Phase 2 N=84 Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
Colitis, Ulcerative
Primary: Fold Change From Baseline in Fecal Calprotectin at Week 14 — 0.41; 0.29; 0.79; 1.24 fold change — p=0.5320
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=235 Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device
Vascular Closure
Primary: The Percentage of Subjects Experiencing a Device or Procedure Related Major Vascular Complication — 2.8 % of subjects with MVCs — p=0.0029
Phase 3 N=940 Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
Acne
Primary: Acne Lesion Percent Reduction — -54.3; -35; -53.5 percent reduction of number of lesions
Phase 2 N=15 Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: The Absolute Difference Between Baseline and Treatment Coefficient of Fat Absorption (CFA) — 6.9 % CFA — p=0.2179
Phase 2 N=118 A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Multiple Myeloma
Primary: Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria — 22.4; 26.5 Percentage of…
N/A N=93 Evaluation of Learning-Theory-Based Smoking Cessation Strategies
Nicotine Dependence
Primary: 4-week Abstinence — 15; 17; 29; 20 participants
Phase 4 N=36 Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
Hypertension · Type 2 Diabetes Mellitus
Primary: Flow Mediated Dilation — 6.2; 4.1 percentage of change in dilation
Phase 4 N=224 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Relapsing Remitting Multiple Sclerosis (RRMS)
Primary: Change From Baseline in the Timed 100-meter Walk Test (T100T) — 86.0; -1.2; -1.6 seconds — p=0.0003
N/A N=91 Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency
Dry Eye Syndrome · Lipid Deficiency
Primary: Mean Bulbar Conjunctival Staining — 0.743; 0.442; 0.531; 0.443 percentage of staining
N/A N=50 Orthotic Use for Chronic Low Back Pain
Chronic Low Back Pain
Primary: Visual Analog Scale (VAS) — 5.0; 4.3; 2.8; 4.1 units on a scale — p=.0007
Phase 2 N=100 Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 95.0; 100.0; 94.7; 94.7 percentage of…
N/A N=21,601 Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study
Awareness During General Anesthesia
Primary: The Percentage of Incidences With Explicit Recall in the BIS Versus MAC Alert Groups. — 0.08; 0.12 Percentage of participants/30days
Phase 2 N=292 Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Chronic Hepatitis C Infection
Primary: Percentage of Participants Who Experienced Adverse Events — 10; 9; 10; 11 Percentage of participants
Phase 4 N=41 Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Brief Pain Inventory (BPI) Change — 5.2; 5.6; 4.9; 4.8 units on a scale — p=0.42
Phase 4 N=501 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Restless Legs Syndrome
Primary: The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score — -12.50; -12.54; -11.48; -9.93 units on a scale…